Key result
New trajectory framework unifies serial right-heart assessment across heart failure using multimodal imaging and biomarkers.
Why the study?
Right-heart metrics critically determine symptoms and outcomes across heart failure, yet longitudinal follow-up remains predominantly left ventricle-centered.
This framework provides a structured approach to longitudinal right-heart monitoring in heart failure, complementing conventional left ventricle-centered assessment.
Answers are grounded in this paper and cite their sources.
Should not yet change right-heart monitoring in HF; leaves open prospective validation of the proposed trajectory framework.
Right ventricular (RV) dysfunction, pulmonary vascular load, tricuspid regurgitation, and venous congestion are important determinants of symptoms and outcomes across the heart failure spectrum, yet longitudinal follow-up remains predominantly left ventricle-centered. This narrative review summarizes the physiological and multimodality imaging basis for serial right-heart assessment across HFrEF, HFmrEF, and HFpEF, using SGLT2 inhibition and dapagliflozin as a contemporary mechanistic example rather than the basis for a drug-specific monitoring algorithm. We propose a pragmatic, therapy-agnostic trajectory framework integrating clinical status, biomarkers, echocardiography, cardiac magnetic resonance, and selective invasive hemodynamics. The approach distinguishes RV dysfunction from overt right-heart failure, incorporates loading conditions, rhythm and tricuspid regurgitation phenotype, and prioritizes serial direction of change over isolated measurements. Emerging SGLT2 inhibitor data provide signals of favorable hemodynamic and RV–pulmonary arterial interaction in selected populations, although dedicated RV-focused randomized evidence remains limited. Suggested reassessment windows are illustrative rather than validated and should be individualized. This framework is intended to complement conventional heart failure assessment and support selective advanced imaging or hemodynamic clarification when clinical and right-heart trajectories are discordant.
No takes yet. Share an insight, caveat, or question.
Albulushi et al. (2026) conducted a review in Heart failure (HFrEF, HFmrEF, HFpEF). Multimodality right-heart monitoring framework was evaluated. A proposed therapy-agnostic trajectory framework integrates clinical status, biomarkers, and multimodality imaging for serial right-heart assessment across the heart failure spectrum.
Synapse has enriched 10 related papers. Consider them for comparative context: